Brought to you by 
Catalent secures $700mm bridge loan commitment to support concurrent Cook Pharmica acquisition
20 Oct 2017
Executive Summary
Catalent Inc., to help finance its concurrent $950mm buy of fellow CRO Cook Pharmica LLC, entered into a $700mm senior unsecured bridge loan facility commitment with Morgan Stanley, JP Morgan Chase, Royal Bank of Canada, RBC Capital Markets, Bank of America Merrill Lynch, and Merrill Lynch Pierce Fenner & Smith Inc. Catalent is also using cash on hand and proceeds from a concurrent public equity offering to fund the acquisition of Cook, and doesn’t expect to borrow under the facility, but it is there if it needs the extra money.
Deal Industry
- Contract Research, Toxicology Testing-CRO
- Pharmaceuticals
- Services
-
Pharmaceuticals
- OTC, Consumer
-
Drug Delivery
- Controlled Release
- Macromolecule
-
Biotechnology
- Drug Discovery Tools
- Synthesis Technologies, Production Processes
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Nonconvertible Debt
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Catalent secures $700mm bridge loan commitment to support concurrent Cook Pharmica acquisition
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice